Social determinants of health in multiple sclerosis

R Dobson, DR Rice, M D'hooghe, R Horne… - Nature Reviews …, 2022 - nature.com
Social determinants of health are the conditions in which people are born, grow, live, work
and age. These circumstances are the non-medical factors that influence health outcomes …

Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort

V Tkachuk, MEB Aguirre, R Alonso, A Barboza… - Multiple sclerosis and …, 2023 - Elsevier
Introduction Neuromyelitis optica spectrum disorder (NMOSD) is a rare but severe
neuroimmunological condition associated with a significant financial burden. NMOSD is also …

[HTML][HTML] The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort

HØ Flemmen, CS Simonsen, L Broch… - Multiple Sclerosis and …, 2022 - Elsevier
Objective Several studies report an impact of socioeconomic factors on access to disease
modifying treatment (DMT) in multiple sclerosis (MS), with a trend of less access to more …

Impact of rituximab in Mexican patients with Multiple Sclerosis–A single-center retrospective study

E Bribiesca-Contreras, C García-Estrada… - Multiple Sclerosis and …, 2022 - Elsevier
Abstract Background Multiple Sclerosis (MS) is a chronic autoimmune disease of the central
nervous system (CNS). B cells have an essential role in the disease pathogenesis and …

Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France

M Lefort, O Dejardin, E Berger… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Background: We hypothesized that differences in access to disease-modifying treatments
(DMTs) could explain the association between socioeconomic status and disability …

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study

MR Hernández-Preciado, J Marquez-Pedroza… - Journal of Clinical …, 2022 - mdpi.com
The objective of this study was to evaluate the clinical files of patients with RRMS who
started rituximab (RTX) compared with a second-line treatment (natalizumab (NTZ) or …

Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico

S Sauri-Suarez, S Quiñones… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Background Cladribine shows efficacy in multiple sclerosis (MS), but Latin American
(LATAM) real-world data is limited, despite potential sociodemographic variations. Objective …

[HTML][HTML] Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis

F Ghadiri, MA Sahraian, F Ashtari… - Archives of Iranian …, 2023 - ncbi.nlm.nih.gov
Background: Multiple sclerosis (MS) may be affected by socioeconomic status (SES). This
study aims to explore the determinants of SES among Iranian patients with MS and examine …

Socioeconomic, health-care access and clinical determinants of disease severity in Multiple Sclerosis in Chile

E Ciampi, B Soler, R Uribe-San-Martin… - Multiple Sclerosis and …, 2023 - Elsevier
Background MS severity may be affected by genetic, patient-related, disease-related and
environmental factors. Socioeconomic status, including income and healthcare access …

Socioeconomic status and quality of multiple sclerosis care in Sweden

A He, A Manouchehrinia, A Glaser… - Multiple Sclerosis and …, 2024 - Elsevier
In Sweden's universal healthcare system, it is unknown whether people of higher
socioeconomic status receive higher quality multiple sclerosis (MS) care. Using linked …